For both patients with ulcerative colitis and those with Crohn disease, psychiatric diagnoses were more common in those who were elderly (greater than 65 years old), women, and white, and those with psychiatric conditions more frequently had a history of alcohol abuse, tobacco and substance abuse, personality disorder, and corticosteroid use.
Treatment with anti-TNFα agents for conditions other than inflammatory bowel disease may increase the risk of developing Crohn disease or ulcerative colitis.
In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment.
Women with Crohn disease who use oral contraceptives for more than 1 year have an increased risk of surgery.
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
Patients with Crohn disease who ate high-fiber foods were 40% less likely to have a disease flare.
A condition prone to recurrence, Crohn disease has a complicated presentation and pathophysiology, but multiple treatment options are available.
Entyvio can be used to treat ulcerative colitis and Crohn disease in adults who did not have success with other treatments.
People with airway diseases are more likely to have inflammatory bowel disease.
